These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 14595343)

  • 1. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 3. More than the sum of their parts? Clustering is becoming more prevalent in the biosciences, despite concerns over the sustainability and economic effectiveness of science parks and hubs.
    Rinaldi A
    EMBO Rep; 2006 Feb; 7(2):133-6. PubMed ID: 16452923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. France to focus on a few biotech clusters.
    Balcon E
    Nat Biotechnol; 2004 Sep; 22(9):1063-4. PubMed ID: 15340457
    [No Abstract]   [Full Text] [Related]  

  • 5. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 6. Germany biotech gets second chance.
    Sheridan C
    Nat Biotechnol; 2003 Dec; 21(12):1414-5. PubMed ID: 14647310
    [No Abstract]   [Full Text] [Related]  

  • 7. India aims to become the main bioinformatics hub.
    Jayaraman KS; Louët S
    Nat Biotechnol; 2004 Aug; 22(8):933. PubMed ID: 15286632
    [No Abstract]   [Full Text] [Related]  

  • 8. Realizing potential: the state of Asian bioentrepreneurship.
    Tang CM; Mahmud MA; Foo FK; Chu SY; Chiu RI; Tanticharoen M; Zhang L; Chang TW
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE15-22. PubMed ID: 12874972
    [No Abstract]   [Full Text] [Related]  

  • 9. Little science, big bucks.
    DeFrancesco L
    Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
    [No Abstract]   [Full Text] [Related]  

  • 10. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 11. New biotech oasis?
    Sheridan C
    Nat Biotechnol; 2005 Aug; 23(8):919. PubMed ID: 16114121
    [No Abstract]   [Full Text] [Related]  

  • 12. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 13. Taiwan: Biotech vision.
    Cyranoski D
    Nat Biotechnol; 2003 Apr; 21(4):463-4. PubMed ID: 12665831
    [No Abstract]   [Full Text] [Related]  

  • 14. China moves to reform biotech policies.
    Jia H
    Nat Biotechnol; 2004 Oct; 22(10):1197. PubMed ID: 15470442
    [No Abstract]   [Full Text] [Related]  

  • 15. The YIC factor.
    Nat Biotechnol; 2005 Oct; 23(10):1187. PubMed ID: 16211041
    [No Abstract]   [Full Text] [Related]  

  • 16. Germany reattempts to spark innovation.
    Habeck M
    Nat Biotechnol; 2004 Mar; 22(3):257-8. PubMed ID: 14990939
    [No Abstract]   [Full Text] [Related]  

  • 17. First U.S.-Russian business venture in closed nuclear city.
    Lopatto J; Wilkes B
    Health Phys; 2004 Feb; 86(2):212-3. PubMed ID: 14744060
    [No Abstract]   [Full Text] [Related]  

  • 18. Boutiques reborn in 2003.
    Surendran A
    Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
    [No Abstract]   [Full Text] [Related]  

  • 19. Superscience me!
    Nat Biotechnol; 2007 Jun; 25(6):604. PubMed ID: 17557082
    [No Abstract]   [Full Text] [Related]  

  • 20. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.